(1) Cox HD, Smeal SJ, Hughes CM, Cox JE, Eichner D
its relevance to retatrutide specifically is not yet established A history of pancreatitis or significant gastrointestinal disease Gallbladder disease , including a history of gallstones or cholecystitis Diabetes mellitus , particularly if managed with insulin or sulphonylureas, due to hypoglycaemia risk Cardiovascular disease , including arrhythmias or recent cardiac events Renal or hepatic impairment , which may affect tolerability and increase the risk of dehydration-related complications Pregnancy or breastfeeding no safety data exist for retatrutide in these groups Use of oral medicines where absorption may be affected by delayed gastric emptying , such as levothyroxine or combined oral contraceptives Seek urgent medical attention if you experience severe or persistent nausea or vomiting, persistent abdominal pain (which may indicate pancreatitis or gallbladder disease), signs of an allergic reaction (rash, swelling, difficulty breathing), chest pain, palpitations, or signs of dehydration
research compound only Product Specifications Format: capsules Strength: 50 mg per capsule Count: 60 capsules per bottle Purity: 99% (HPLC verified) Container: sealed amber bottle Certificate of Analysis: lot-specific COA available See the FDA Disclosure, Storage Instructions, and RUO tabs for handling, storage, and regulatory information
The tesofensine article covers a compound that approaches weight loss through neurotransmitter modulation, providing appetite suppression through a completely different mechanism than GLP-1 agonists
